

# Bruce A Perkins

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5212505/publications.pdf>

Version: 2024-02-01

195  
papers

13,199  
citations

30070

54  
h-index

24258

110  
g-index

196  
all docs

196  
docs citations

196  
times ranked

11582  
citing authors

#	ARTICLE	IF	CITATIONS
1	The association between physical activity time and neuropathy in longstanding type 1 diabetes: A cross-sectional analysis of the Canadian study of longevity in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108134.	2.3	5
2	Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes. <i>Diabetes Care</i> , 2022, 45, 585-593.	8.6	1
3	Orthostatic blood pressure changes and diabetes duration. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108169.	2.3	2
4	The uncomfortable truth about kidney disease in type 1 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 472-473.	11.4	3
5	Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2â€‰Ã—â€‰2 factorial randomized crossover trial. <i>Nature Medicine</i> , 2022, 28, 1269-1276.	30.7	20
6	SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis. <i>Current Diabetes Reports</i> , 2022, 22, 317-332.	4.2	4
7	Baseline omega-3 level is associated with nerve regeneration following 12-months of omega-3 nutrition therapy in patients with type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107798.	2.3	10
8	Impact of a Gluten-Free Diet on Quality of Life and Health Perception in Patients With Type 1 Diabetes and Asymptomatic Celiac Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1984-e1992.	3.6	7
9	Reducing the need for carbohydrate counting in type 1 diabetes using closedâ€‰loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, nonâ€‰inferiority, crossover pilot trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1272-1281.	4.4	19
10	Vasopressin associated with renal vascular resistance in adults with longstanding type 1 diabetes with and without diabetic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107807.	2.3	8
11	Discoveries from the study of longstanding type 1 diabetes. <i>Diabetologia</i> , 2021, 64, 1189-1200.	6.3	12
12	Vitamin D Levels and the Risk of Posttransplant Diabetes Mellitus After Kidney Transplantation. <i>Progress in Transplantation</i> , 2021, 31, 133-141.	0.7	2
13	Relationships between inflammation, hemodynamic function and RAAS in longstanding type 1 diabetes and diabetic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107880.	2.3	8
14	Glycaemic control in transitionâ€‰aged versus early adults with type 1 diabetes and the effect of a governmentâ€‰funded insulin pump programme. <i>Diabetic Medicine</i> , 2021, 38, e14618.	2.3	1
15	Type 1 diabetes glycemic management: Insulin therapy, glucose monitoring, and automation. <i>Science</i> , 2021, 373, 522-527.	12.6	43
16	Corneal Confocal Microscopy Predicts the Development of Diabetic Neuropathy: A Longitudinal Diagnostic Multinational Consortium Study. <i>Diabetes Care</i> , 2021, 44, 2107-2114.	8.6	28
17	Afternoon aerobic and resistance exercise have limited impact on 24-h CGM outcomes in adults with type 1 diabetes: A secondary analysis. <i>Diabetes Research and Clinical Practice</i> , 2021, 177, 108874.	2.8	4
18	Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2466-2475.	4.4	17

#	ARTICLE	IF	CITATIONS
19	The Prevalence of Autoimmune Diseases in Longstanding Diabetes: Results from the Canadian Study of Longevity in Adults with Type 1 Diabetes. <i>Canadian Journal of Diabetes</i> , 2021, 45, 512-518.e1.	0.8	4
20	Kidney Effects of Empagliflozin in People with Type 1 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1715-1719.	4.5	13
21	Omega-3 Nutrition Therapy for the Treatment of Diabetic Sensorimotor Polyneuropathy. <i>Current Diabetes Reviews</i> , 2021, 17, .	1.3	1
22	SGLT2â€inhibition reverts urinary peptide changes associated with severe COVIDâ€19: An inâ€silico proofâ€ofâ€principle of proteomicsâ€based drug repurposing. <i>Proteomics</i> , 2021, 21, e2100160.	2.2	3
23	Allopurinol and Renal Outcomes in Adults With and Without Type 2 Diabetes: A Retrospective, Population-Based Cohort Study and Propensity Score Analysis. <i>Canadian Journal of Diabetes</i> , 2021, 45, 641-649.e4.	0.8	3
24	Allopurinol adherence, persistence and patterns of use in individuals with diabetes and gout: A retrospective, population-based cohort analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1162-1169.	3.4	4
25	Impact of government-funded insulin pump programs on insulin pump use in Canada: a cross-sectional study using the National Diabetes Repository. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, .	2.8	1
26	Impact of government-funded insulin pump programs on insulin pump use in Canada: a cross-sectional study using the National Diabetes Repository. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002371.	2.8	7
27	Analysis of Prevalence, Magnitude and Timing of the Dawn Phenomenon in Adults and Adolescents With Type 1 Diabetes: Descriptive Analysis of 2 Insulin Pump Trials. <i>Canadian Journal of Diabetes</i> , 2020, 44, 229-235.	0.8	11
28	Graves' Disease After Chronic Hypothyroidism in Type 1 Diabetes. <i>Canadian Journal of Diabetes</i> , 2020, 44, 131-132.	0.8	1
29	Talking Points for Helping Your Type 1 Diabetes Patient Decide About Hybrid Closed Loop. <i>Canadian Journal of Diabetes</i> , 2020, 44, 356-358.	0.8	4
30	Lowâ€dose empagliflozin as adjunctâ€toâ€insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 427-433.	4.4	8
31	High fractional excretion of glycation adducts is associated with subsequent early decline in renal function in type 1 diabetes. <i>Scientific Reports</i> , 2020, 10, 12709.	3.3	10
32	18 - Empagliflozin Is Associated With Increased Plasma Lipid Metabolites in Type 1 Diabetes. <i>Canadian Journal of Diabetes</i> , 2020, 44, S7-S8.	0.8	0
33	Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study. <i>Diabetes Care</i> , 2020, 43, 1553-1556.	8.6	19
34	Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2020, 382, 2493-2503.	27.0	228
35	Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors inâ€hyperfiltering people with type 1 diabetes andâ€people with type 2 diabetes and normal kidney function. <i>Kidney International</i> , 2020, 97, 631-635.	5.2	29
36	Rethinking Neuropathy in Type 1 Diabetes: Had We Lost Sight of What Matters Most?. <i>Diabetes Care</i> , 2020, 43, 695-697.	8.6	4

#	ARTICLE	IF	CITATIONS
37	Rapid Corneal Nerve Fiber Loss: A Marker of Diabetic Neuropathy Onset and Progression. <i>Diabetes Care</i> , 2020, 43, 1829-1835.	8.6	40
38	Randomized, controlled crossover study of IVIg for demyelinating polyneuropathy and diabetes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	6.0	4
39	Sex differences in neuropathy & neuropathic pain: A brief report from the Phase 2 Canadian Study of Longevity in Type 1 Diabetes. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 107397.	2.3	8
40	126 - Prevalence of Detectable C-peptide in Longstanding Type 1 Diabetes (T1D). <i>Canadian Journal of Diabetes</i> , 2019, 43, S43.	0.8	1
41	Elevated plasma cyclic guanosine monophosphate may explain greater efferent arteriolar tone in adults with longstanding type 1 diabetes: A brief report. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 547-549.	2.3	1
42	A Genetic Locus on Chromosome 2q24 Predicting Peripheral Neuropathy Risk in Type 2 Diabetes: Results From the ACCORD and BARI 2D Studies. <i>Diabetes</i> , 2019, 68, 1649-1662.	0.6	22
43	Estimating GFR by Serum Creatinine, Cystatin C, and $\beta$ 2-Microglobulin in Older Adults: Results From the Canadian Study of Longevity in Type 1 Diabetes. <i>Kidney International Reports</i> , 2019, 4, 786-796.	0.8	12
44	Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1716-1723.	8.6	10
45	Risk factors for diabetic kidney disease in adults with longstanding type 1 diabetes: results from the Canadian Study of Longevity in Diabetes. <i>Renal Failure</i> , 2019, 41, 427-433.	2.1	4
46	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinolâ€”Rationale, Design, and Baseline Data. <i>Diabetes Care</i> , 2019, 42, 1454-1463.	8.6	39
47	Authors' reply to: â€œThe role of longâ€term effects of allopurinol on cardiovascular outcomes and allâ€cause mortality in diabetesâ€: <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2181-2182.	4.4	0
48	Uric Acid Levels Correlate with Sensory Nerve Function in Healthy Subjects. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 337-341.	0.5	4
49	Risk Factors for Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 883-890.	8.6	76
50	Molecular regulation of the reninâ€angiotensin system by sodiumâ€glucose cotransporter 2 inhibition in type 1 diabetes mellitus. <i>Diabetologia</i> , 2019, 62, 1090-1093.	6.3	21
51	Renal Hemodynamic Function and RAAS Activation Over the Natural History of Type 1 Diabetes. <i>American Journal of Kidney Diseases</i> , 2019, 73, 786-796.	1.9	15
52	Association between allopurinol and cardiovascular outcomes and allâ€cause mortality in diabetes: A retrospective, populationâ€based cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1322-1329.	4.4	20
53	Association between uric acid, renal haemodynamics and arterial stiffness over the natural history of type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1388-1398.	4.4	12
54	Sounding the alarm on rising diabetes-related amputations. <i>Cmaj</i> , 2019, 191, E953-E954.	2.0	3

#	ARTICLE	IF	CITATIONS
55	Bone mineral density in patients with longstanding type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 107324.	2.3	21
56	The relationships between markers of tubular injury and intrarenal haemodynamic function in adults with and without type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 575-583.	4.4	15
57	Retinopathy and RAAS Activation: Results From the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 273-280.	8.6	16
58	Laboratory Abnormalities in Polyneuropathy and Electrophysiological Correlations. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, 346-349.	0.5	3
59	Sex differences in neuropathic pain intensity in diabetes. <i>Journal of the Neurological Sciences</i> , 2018, 388, 103-106.	0.6	38
60	Neuropathy. <i>Canadian Journal of Diabetes</i> , 2018, 42, S217-S221.	0.8	36
61	Adiposity Impacts Intrarenal Hemodynamic Function in Adults With Long-standing Type 1 Diabetes With and Without Diabetic Nephropathy: Results From the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes Care</i> , 2018, 41, 831-839.	8.6	13
62	Nerve function varies with hemoglobin A1c in controls and type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 424-428.	2.3	5
63	High frequency of MGUS in DSP. <i>Muscle and Nerve</i> , 2018, 57, 1018-1021.	2.2	0
64	Cramps frequency and severity are correlated with small and large nerve fiber measures in type 1 diabetes. <i>Clinical Neurophysiology</i> , 2018, 129, 122-126.	1.5	8
65	Diabetes Care Disparities in Long-standing Type 1 Diabetes in Canada and the U.S.: A Cross-sectional Comparison. <i>Diabetes Care</i> , 2018, 41, 88-95.	8.6	17
66	Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. <i>Diabetes Care</i> , 2018, 41, 2560-2569.	8.6	239
67	Atherosclerosis and Microvascular Complications: Results From the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes Care</i> , 2018, 41, 2570-2578.	8.6	37
68	Sex differences in neuropathic pain in longstanding diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 660-664.	2.3	22
69	Corneal confocal microscopy for identification of diabetic sensorimotor polyneuropathy: a pooled multinational consortium study. <i>Diabetologia</i> , 2018, 61, 1856-1861.	6.3	103
70	Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes. <i>JCI Insight</i> , 2018, 3, .	5.0	38
71	Validity of a point-of-care nerve conduction device for polyneuropathy identification in older adults with diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. <i>PLoS ONE</i> , 2018, 13, e0196647.	2.5	13
72	Peripheral nerve high-resolution ultrasound in diabetes. <i>Muscle and Nerve</i> , 2017, 55, 171-178.	2.2	64

#	ARTICLE	IF	CITATIONS
73	Using in vivo corneal confocal microscopy to identify diabetic sensorimotor polyneuropathy risk profiles in patients with type 1 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000251.	2.8	15
74	Renal and Vascular Effects of Uric Acid Lowering in Normouricemic Patients With Uncomplicated Type 1 Diabetes. <i>Diabetes</i> , 2017, 66, 1939-1949.	0.6	28
75	Effect of omega-3 supplementation on neuropathy in type 1 diabetes. <i>Neurology</i> , 2017, 88, 2294-2301.	1.1	95
76	Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 501-512.	11.4	348
77	Neuropathy and presence of emotional distress and depression in longstanding diabetes: Results from the Canadian study of longevity in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1318-1324.	2.3	37
78	Uric acid levels correlate with the severity of diabetic sensorimotor polyneuropathy. <i>Journal of the Neurological Sciences</i> , 2017, 379, 94-98.	0.6	12
79	Urinary adenosine excretion in type 1 diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, F184-F191.	2.7	46
80	Assessment of urinary microparticles in normotensive patients with type 1 diabetes. <i>Diabetologia</i> , 2017, 60, 581-584.	6.3	65
81	Clinical characteristics, and impairment and disability scale scores for different CIDP Disease Activity Status classes. <i>Journal of the Neurological Sciences</i> , 2017, 372, 223-227.	0.6	13
82	Meta-analysis of artificial pancreas trials: methodological considerations – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 685-686.	11.4	2
83	Biomarkers of tubulointerstitial damage and function in type 1 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000461.	2.8	9
84	Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon?. <i>Canadian Journal of Diabetes</i> , 2017, 41, 6-9.	0.8	12
85	Agreement between automated and manual quantification of corneal nerve fiber length: Implications for diabetic neuropathy research. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1066-1073.	2.3	26
86	The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome. <i>PLoS ONE</i> , 2017, 12, e0186910.	2.5	21
87	Lower corneal nerve fibre length identifies diabetic neuropathy in older adults with diabetes: results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetologia</i> , 2017, 60, 2529-2531.	6.3	14
88	Reference values for ultrasonography of peripheral nerves. <i>Muscle and Nerve</i> , 2016, 53, 538-544.	2.2	66
89	No Need to Sugarcoat the Message: Is Cardiovascular Risk Reduction From SGLT2 Inhibition Related to Natriuresis?. <i>American Journal of Kidney Diseases</i> , 2016, 68, 349-352.	1.9	18
90	Prevalence of Insulin Pump Therapy and Its Association with Measures of Glycemic Control: Results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 298-307.	4.4	25

#	ARTICLE	IF	CITATIONS
91	A rapid decline in corneal small fibers and occurrence of foot ulceration and Charcot foot. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1437-1439.	2.3	21
92	Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus. <i>Circulation</i> , 2016, 134, 752-772.	1.6	932
93	Disease activity in chronic inflammatory demyelinating polyneuropathy. <i>Journal of the Neurological Sciences</i> , 2016, 369, 204-209.	0.6	11
94	Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1969-1977.	4.5	93
95	Frequent laboratory abnormalities in CIDP patients. <i>Muscle and Nerve</i> , 2016, 53, 862-865.	2.2	18
96	Cardiovascular disease guideline adherence and self-reported statin use in longstanding type 1 diabetes: results from the Canadian study of longevity in diabetes cohort. <i>Cardiovascular Diabetology</i> , 2016, 15, 14.	6.8	29
97	The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. <i>Diabetologia</i> , 2016, 59, 1860-1870.	6.3	148
98	Validation of cooling detection threshold as a marker of sensorimotor polyneuropathy in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 716-722.	2.3	20
99	Commonly Measured Clinical Variables Are Not Associated With Burden of Complications in Long-standing Type 1 Diabetes: Results From the Canadian Study of Longevity in Diabetes. <i>Diabetes Care</i> , 2016, 39, e67-e68.	8.6	19
100	Laser Doppler Flare Imaging and Quantitative Thermal Thresholds Testing Performance in Small and Mixed Fiber Neuropathies. <i>PLoS ONE</i> , 2016, 11, e0165731.	2.5	33
101	Elevated Vibration Perception Thresholds in CIDP Patients Indicate More Severe Neuropathy and Lower Treatment Response Rates. <i>PLoS ONE</i> , 2015, 10, e0139689.	2.5	8
102	Reproducibility of In Vivo Corneal Confocal Microscopy Using an Automated Analysis Program for Detection of Diabetic Sensorimotor Polyneuropathy. <i>PLoS ONE</i> , 2015, 10, e0142309.	2.5	37
103	The Celiac Disease and Diabetes-Dietary Intervention and Evaluation Trial (CD-DIET) protocol: a randomised controlled study to evaluate treatment of asymptomatic coeliac disease in type 1 diabetes. <i>BMJ Open</i> , 2015, 5, e008097-e008097.	1.9	23
104	Diabetic Neuropathies. <i>Seminars in Neurology</i> , 2015, 35, 424-430.	1.4	21
105	Sensor-Augmented Pump and Multiple Daily Injection Therapy in the United States and Canada: Post-Hoc Analysis of a Randomized Controlled Trial. <i>Canadian Journal of Diabetes</i> , 2015, 39, 50-54.	0.8	5
106	Resistance Exercise in Already-Active Diabetic Individuals (READI): Study rationale, design and methods for a randomized controlled trial of resistance and aerobic exercise in type 1 diabetes. <i>Contemporary Clinical Trials</i> , 2015, 41, 129-138.	1.8	10
107	Corneal Confocal Microscopy Predicts 4-Year Incident Peripheral Neuropathy in Type 1 Diabetes. <i>Diabetes Care</i> , 2015, 38, 671-675.	8.6	129
108	Uric Acid as a Biomarker and a Therapeutic Target in Diabetes. <i>Canadian Journal of Diabetes</i> , 2015, 39, 239-246.	0.8	103

#	ARTICLE	IF	CITATIONS
109	Cardiac Autonomic Neuropathy and Early Progressive Renal Decline in Patients with Nonmacroalbuminuric Type 1 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1136-1144.	4.5	41
110	Treatment responsiveness in CIDP patients with diabetes is associated with unique electrophysiological characteristics, and not with common criteria for CIDP. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 537-546.	3.0	13
111	Choosing drugs for the treatment of diabetic neuropathy. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1805-1814.	1.8	6
112	Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. <i>Journal of Neuro-Oncology</i> , 2015, 124, 119-126.	2.9	67
113	Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort. <i>Diabetes Care</i> , 2015, 38, 793-800.	8.6	104
114	Normative Values for Corneal Nerve Morphology Assessed Using Corneal Confocal Microscopy: A Multinational Normative Data Set. <i>Diabetes Care</i> , 2015, 38, 838-843.	8.6	150
115	Evaluation of a Clinical Tool to Test and Adjust the Programmed Overnight Basal Profiles for Insulin Pump Therapy: A Pilot Study. <i>Canadian Journal of Diabetes</i> , 2015, 39, 364-372.	0.8	4
116	In Vivo Corneal Confocal Microscopy and Prediction of Future-Incident Neuropathy in Type 1 Diabetes: A Preliminary Longitudinal Analysis. <i>Canadian Journal of Diabetes</i> , 2015, 39, 390-397.	0.8	57
117	Validation of Cooling Detection Threshold as a Marker of Sensorimotor Polyneuropathy in Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2015, 39, 542.	0.8	0
118	Reproducibility of In Vivo Corneal Confocal Microscopy Using an Automated Analysis Program for Detection of Diabetic Sensorimotor Polyneuropathy. <i>Canadian Journal of Diabetes</i> , 2015, 39, 543.	0.8	0
119	Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 308, F77-F83.	2.7	143
120	Treatment Responsiveness in CIDP Patients with Diabetes Is Associated with Higher Degrees of Demyelination. <i>PLoS ONE</i> , 2015, 10, e0139674.	2.5	9
121	Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes. <i>PLoS ONE</i> , 2015, 10, e0141085.	2.5	28
122	Reliability and Validity of a Point-of-Care Sural Nerve Conduction Device for Identification of Diabetic Neuropathy. <i>PLoS ONE</i> , 2014, 9, e86515.	2.5	72
123	The Characteristics of Chronic Inflammatory Demyelinating Polyneuropathy in Patients with and without Diabetes – An Observational Study. <i>PLoS ONE</i> , 2014, 9, e89344.	2.5	29
124	Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. <i>Kidney International</i> , 2014, 86, 1057-1058.	5.2	93
125	Response to Comment on Breiner et al. Does the Prevailing Hypothesis That Small-Fiber Dysfunction Precedes Large-Fiber Dysfunction Apply to Type 1 Diabetic Patients? <i>Diabetes Care</i> 2014;37:1418-1424. <i>Diabetes Care</i> , 2014, 37, e242-e242.	8.6	1
126	Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial. <i>Diabetes Care</i> , 2014, 37, 1480-1483.	8.6	211



#	ARTICLE	IF	CITATIONS
127	White blood cell subtypes, insulin resistance and Î²â€cell dysfunction in highâ€risk individuals â€ the PROMISE cohort. <i>Clinical Endocrinology</i> , 2014, 81, 536-541.	2.4	41
128	Does the Prevailing Hypothesis That Small-Fiber Dysfunction Precedes Large-Fiber Dysfunction Apply to Type 1 Diabetic Patients?. <i>Diabetes Care</i> , 2014, 37, 1418-1424.	8.6	105
129	Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. <i>Diabetologia</i> , 2014, 57, 2599-2602.	6.3	136
130	Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus. <i>Circulation</i> , 2014, 129, 587-597.	1.6	1,045
131	The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2014, 13, 28.	6.8	381
132	Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: Simultaneous Glucose Lowering and Renal Protection?. <i>Canadian Journal of Diabetes</i> , 2014, 38, 356-363.	0.8	35
133	Prospective association of 25(OH)D with metabolic syndrome. <i>Clinical Endocrinology</i> , 2014, 80, 502-507.	2.4	44
134	Measurement of Cooling Detection Thresholds for Identification of Diabetic Sensorimotor Polyneuropathy in Type 1 Diabetes. <i>PLoS ONE</i> , 2014, 9, e106995.	2.5	14
135	Uric Acid Lowering to Prevent Kidney Function Loss in Diabetes: The Preventing Early Renal Function Loss (PERL) Allopurinol Study. <i>Current Diabetes Reports</i> , 2013, 13, 550-559.	4.2	127
136	Resistance Exercise in Type 1 Diabetes. <i>Canadian Journal of Diabetes</i> , 2013, 37, 420-426.	0.8	38
137	Conduction Slowing in Diabetic Sensorimotor Polyneuropathy. <i>Diabetes Care</i> , 2013, 36, 3684-3690.	8.6	63
138	Insulin Pump Therapy Is Associated with Less Post-Exercise Hyperglycemia than Multiple Daily Injections: An Observational Study of Physically Active Type 1 Diabetes Patients. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 84-88.	4.4	71
139	The impact of common variation in the definition of diabetic sensorimotor polyneuropathy on the validity of corneal in vivo confocal microscopy in patients with type 1 diabetes: a brief report. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 240-242.	2.3	15
140	Resistance Versus Aerobic Exercise. <i>Diabetes Care</i> , 2013, 36, 537-542.	8.6	184
141	Impact of Glycemic Control Strategies on the Progression of Diabetic Peripheral Neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. <i>Diabetes Care</i> , 2013, 36, 3208-3215.	8.6	128
142	Comparison of diabetes patients with â€demyelinatingâ€ diabetic sensorimotor polyneuropathy to those diagnosed with <sc>CIDP</sc>. <i>Brain and Behavior</i> , 2013, 3, 656-663.	2.2	21
143	Point Accuracy of Interstitial Continuous Glucose Monitoring During Exercise in Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 46-49.	4.4	47
144	Structure-Function Relationship Between Corneal Nerves and Conventional Small-Fiber Tests in Type 1 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2748-2755.	8.6	83

#	ARTICLE	IF	CITATIONS
145	Identification and Prediction of Diabetic Sensorimotor Polyneuropathy Using Individual and Simple Combinations of Nerve Conduction Study Parameters. PLoS ONE, 2013, 8, e58783.	2.5	58
146	Renal Hyperfiltration and Systemic Blood Pressure in Patients with Uncomplicated Type 1 Diabetes Mellitus. PLoS ONE, 2013, 8, e68908.	2.5	23
147	Performing Resistance Exercise Prior to Aerobic Exercise Results in Higher Growth Hormone Levels during Exercise in Physically Active Individuals with Well-€Controlled Type 1 Diabetes. FASEB Journal, 2013, 27, 712.29.	0.5	0
148	Ability of Cystatin C to Detect Changes in Glomerular Filtration Rate After ACE Inhibition in Patients with Uncomplicated Type 1 Diabetes. Clinical and Experimental Hypertension, 2012, 34, 606-611.	1.3	6
149	Detection of Diabetic Sensorimotor Polyneuropathy by Corneal Confocal Microscopy in Type 1 Diabetes. Diabetes Care, 2012, 35, 821-828.	8.6	177
150	Heart Rate Variability and Sensorimotor Polyneuropathy in Type 1 Diabetes. Diabetes Care, 2012, 35, 809-816.	8.6	31
151	Effects of Performing Resistance Exercise Before Versus After Aerobic Exercise on Glycemia in Type 1 Diabetes. Diabetes Care, 2012, 35, 669-675.	8.6	154
152	The clinical landscape of painful diabetic neuropathy therapy: perspectives for clinicians from clinical practice guidelines. Clinical Investigation, 2012, 2, 483-489.	0.0	1
153	Can Ultrasound of the Tibial Nerve Detect Diabetic Peripheral Neuropathy?. Diabetes Care, 2012, 35, 2575-2579.	8.6	92
154	Can Improved Glycemic Control Slow Renal Function Decline at All Stages of Diabetic Nephropathy?. Seminars in Nephrology, 2012, 32, 423-431.	1.6	9
155	Higher magnification lenses versus conventional lenses for evaluation of diabetic neuropathy by corneal in vivo confocal microscopy. Diabetes Research and Clinical Practice, 2012, 97, e37-e40.	2.8	12
156	Point Accuracy of Interstitial Continuous Glucose Monitoring During Resistance and Aerobic Exercise in Type 1 Diabetes. Canadian Journal of Diabetes, 2012, 36, S14-S15.	0.8	3
157	Identification and 4-year Prediction of Diabetic Sensorimotor Polyneuropathy Using Individual and Simple Combinations of Nerve Conduction Study Parameters. Canadian Journal of Diabetes, 2012, 36, S51-S52.	0.8	0
158	Diabetic Neuropathy and Axon Reflex-Mediated Neurogenic Vasodilatation in Type 1 Diabetes. PLoS ONE, 2012, 7, e34807.	2.5	22
159	Serum Levels of Advanced Glycation Endproducts and Other Markers of Protein Damage in Early Diabetic Nephropathy in Type 1 Diabetes. PLoS ONE, 2012, 7, e35655.	2.5	46
160	Sural-€to-€radial amplitude ratio in the diagnosis of diabetic sensorimotor polyneuropathy. Muscle and Nerve, 2012, 45, 126-127.	2.2	15
161	Association of 25(OH)D and PTH with Metabolic Syndrome and Its Traditional and Nontraditional Components. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 168-175.	3.6	107
162	How sensitive is the case definition for diabetic sensorimotor polyneuropathy to the use of different symptoms, signs, and nerve conduction parameters in Type 1 diabetes?. Diabetes Research and Clinical Practice, 2011, 92, e16-e19.	2.8	6

#	ARTICLE	IF	CITATIONS
163	Dorsal versus ventral monofilament testing of the great toe for the identification of diabetic sensorimotor polyneuropathy. <i>Diabetes Research and Clinical Practice</i> , 2011, 93, e71-e73.	2.8	3
164	Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study. <i>Diabetes Care</i> , 2011, 34, 2403-2405.	8.6	102
165	Prospective Associations of Vitamin D With $\beta$ -Cell Function and Glycemia. <i>Diabetes</i> , 2011, 60, 2947-2953.	0.6	124
166	In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. <i>Kidney International</i> , 2010, 77, 57-64.	5.2	231
167	Prediction of Incident Diabetic Neuropathy Using the Monofilament Examination. <i>Diabetes Care</i> , 2010, 33, 1549-1554.	8.6	80
168	Association of Vitamin D With Insulin Resistance and $\beta$ -Cell Dysfunction in Subjects at Risk for Type 2 Diabetes. <i>Diabetes Care</i> , 2010, 33, 1379-1381.	8.6	287
169	Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2010, 363, 311-320.	27.0	792
170	Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring. <i>Journal of Diabetes Science and Technology</i> , 2009, 3, 914-923.	2.2	99
171	Renal Hyperfiltration and the Development of Microalbuminuria in Type 1 Diabetes. <i>Diabetes Care</i> , 2009, 32, 889-893.	8.6	76
172	Diabetes Complications and the Renin-Angiotensin System. <i>New England Journal of Medicine</i> , 2009, 361, 83-85.	27.0	24
173	Urinary Peptidome May Predict Renal Function Decline in Type 1 Diabetes and Microalbuminuria. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 2065-2074.	6.1	136
174	The consequences of anxious temperament for disease detection, self-management behavior, and quality of life in Type 2 diabetes mellitus. <i>Journal of Psychosomatic Research</i> , 2009, 67, 297-305.	2.6	40
175	Early nephropathy in type 1 diabetes: the importance of early renal function decline. <i>Current Opinion in Nephrology and Hypertension</i> , 2009, 18, 233-240.	2.0	53
176	Multi-Site Testing With a Point-of-Care Nerve Conduction Device Can Be Used in an Algorithm to Diagnose Diabetic Sensorimotor Polyneuropathy. <i>Diabetes Care</i> , 2008, 31, 522-524.	8.6	23
177	Determinants of Progression from Microalbuminuria to Proteinuria in Patients Who Have Type 1 Diabetes and Are Treated with Angiotensin-Converting Enzyme Inhibitors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 461-469.	4.5	49
178	Microalbuminuria and the Risk for Early Progressive Renal Function Decline in Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1353-1361.	6.1	325
179	Type 1 Diabetes and Vigorous Exercise: Applications of Exercise Physiology to Patient Management. <i>Canadian Journal of Diabetes</i> , 2006, 30, 63-71.	0.8	110
180	Type 1 Diabetes and Exercise: Using the Insulin Pump to Maximum Advantage. <i>Canadian Journal of Diabetes</i> , 2006, 30, 72-79.	0.8	49

#	ARTICLE	IF	CITATIONS
181	Efficacy of Continuous Real-Time Blood Glucose Monitoring During and After Prolonged High-Intensity Cycling Exercise: Spinning with a Continuous Glucose Monitoring System. <i>Diabetes Technology and Therapeutics</i> , 2006, 8, 627-635.	4.4	89
182	Validation of a Novel Point-of-Care Nerve Conduction Device for the Detection of Diabetic Sensorimotor Polyneuropathy. <i>Diabetes Care</i> , 2006, 29, 2023-2027.	8.6	53
183	Objective Evidence for the Reversibility of Nerve Injury in Diabetic Neuropathic Cachexia. <i>Diabetes Care</i> , 2006, 29, 473-474.	8.6	9
184	Early nephropathy in type 1 diabetes: A new perspective on who will and who will not progress. <i>Current Diabetes Reports</i> , 2005, 5, 455-463.	4.2	50
185	Emerging Therapies for Diabetic Neuropathy: A Clinical Overview. <i>Current Diabetes Reviews</i> , 2005, 1, 271-280.	1.3	11
186	Early Vascular Risk Factor Modification in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2005, 352, 408-409.	27.0	8
187	Detection of Renal Function Decline in Patients with Diabetes and Normal or Elevated GFR by Serial Measurements of Serum Cystatin C Concentration. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1404-1412.	6.1	307
188	Cooling Detection Thresholds in the Assessment of Diabetic Sensory Polyneuropathy: Comparison of CASE IV and Medoc instruments. <i>Diabetes Care</i> , 2004, 27, 1674-1679.	8.6	42
189	Diabetic neuropathy: a review emphasizing diagnostic methods. <i>Clinical Neurophysiology</i> , 2003, 114, 1167-1175.	1.5	139
190	Regression of Microalbuminuria in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2003, 348, 2285-2293.	27.0	719
191	Validation of the Toronto Clinical Scoring System for Diabetic Polyneuropathy. <i>Diabetes Care</i> , 2002, 25, 2048-2052.	8.6	341
192	Carpal Tunnel Syndrome in Patients With Diabetic Polyneuropathy. <i>Diabetes Care</i> , 2002, 25, 565-569.	8.6	241
193	Symmetry of nerve conduction studies in different stages of diabetic polyneuropathy. <i>Muscle and Nerve</i> , 2002, 25, 212-217.	2.2	28
194	Diagnosis and management of diabetic neuropathy. <i>Current Diabetes Reports</i> , 2002, 2, 495-500.	4.2	32
195	Evaluation of three screening tests and a risk assessment model for diagnosing peripheral neuropathy in the diabetes clinic. <i>Diabetes Research and Clinical Practice</i> , 2001, 54, 115-128.	2.8	123